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Stem cells, known by their ability to repair damaged tissue, are often explored 
in regenerative therapies. The umbilical cord outer lining membrane was found 
to be a promising source of multi-potent stem cells. By cultivating the 
membrane in an epithelial cell growth medium, the cell population was found 
to possess the properties of both epithelial cells and embryonic stem cells. These 
cells were termed Cord Lining Epithelial Cells (CLEC). 
Hepatocytes are epithelial cells and their proliferation upon liver injury is the 
main mechanism in restoring the liver. Earlier studies conducted showed that 
CLEC was able to be differentiated into functioning hepatocyte-like cells (HLC) 
and survive in immunologically competent specimens. 
This study chooses porcine as a study model in developing CLEC as a treatment 
modality for liver failure. It aims to investigate the transplantation toxicity of 
HLC, unique cell delivery method and its enhancement effects on liver 
insufficient porcine models. 
16 Yorkshire-Dutch Landrace pigs, with a mean weight of 40.5 kg were selected 
in this study. 50% hepatectomy was performed to simulate the liver 
insufficiency disease model. After the surgery, 4 pigs were transplanted with 
saline scaffold (control) while 7 pigs were transplanted with HLC scaffold 
(study). The remaining 5 pigs died on the surgical table and were left out from 
the study analysis. 
The surviving pigs were studied for the subsequent 3 weeks. Liver function 
blood tests, computed tomography (CT) scans, CT-guided needle biopsy at 
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selected intervals were performed. At the end of 3 weeks, all subjects were 
sacrificed unless advised by the veterinarians for earlier termination. Liver 
volumetric data was collected throughout the 3-week survival period. The 
excised liver and biopsy tissue samples were examined histologically.  
DeRitis ratio, blood prothrombin clotting time, serum alkaline phosphatase and 
liver volume data showed no statistically significant difference between the two 
groups. One subject from the control group and the study group were euthanized 
before the end of post-operative 3 weeks due to intestinal adhesion. Liver biopsy 
samples showed minimal and non-specific reactions in both groups. Histology 
study showed the collagen scaffold were absorbed by the host within 3 weeks. 
No signs of significant cellular rejection were observed along the transplant 
interfaces. Immunohistochemistry staining showed HLC survived within 
immunologically-competent pigs for 3 weeks after transplantation.  
From this study, the group concluded that HLC poses insignificant toxicity in a 
xeno-transplantation model as no significant difference were observed between 
the study and control group. No immune-rejection response was elicited in the 
study subjects. The unique cell delivery method transported HLC to the host 
with 3 weeks’ survival but cells were attached to the scaffold surface 
superficially. While a positive trend was developing, HLC did not show 
significant effect in accelerating liver regeneration nor increasing liver function 
throughout the 3 weeks’ post-transplantation in this study.
  






Liver disease is a huge burden to public health globally. In 2010, mortality due 
to liver diseases accounted for over 2 million deaths, approximately 4% of all 
deaths in the world [1]. As the patient’s liver degenerates, transplantation of 
another liver, either from a deceased person or a living donor, is often the only 
available curative treatment. According to the 2012 Scientific Registry of 
Transplant Recipients, there were 10,000 new candidates added to the United 
States liver transplant waiting list, but only about 6,000 liver transplantations 
were performed that year [2]. With a shortage of liver donors, alternate forms 
of treatment therapy are heavily investigated to meet the demands of increasing 
liver failure incidence rates worldwide. 
Our research aims to use hepatocyte-like cells (HLC) derived from Human Cord 
Lining Epithelial Cells (CLEC) as a mean to enhance liver regeneration, before 
the liver worsens to a stage in which regeneration is not possible, such as the 
formation of regenerative nodules. Patients suffering from acute liver failure 
due to drugs or post-surgery and patients suffering from chronic liver disorders 
stand to benefit the most from accelerated liver regeneration. This initial study 
aims to investigate the safety of implanted HLC in the recovery of pigs that have 
undergone extensive hepatectomy and the effectiveness of the unique delivery 
method.   
Objectives 
The main objectives of this project were as listed:  
1. To evaluate the toxicity of HLC in a xeno-transplanted model:  
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a. Viability of HLC and signs of cellular rejection along transplant 
interface in hosts after 3 weeks were investigated  
b. Overall health of subjects over the period of 3 weeks after 
transplantation of HLC were observed 
2. To evaluate the effectiveness of novel cell delivery method – placing 
collagen scaffold directly on resected liver surface: 
a. Histological study of collagen scaffold, before and after transplantation 
were carried out 
3. To investigate the effectiveness of HLC in enhancing liver regeneration on 
liver insufficient porcine models: 
a. Liver function tests (LFT) and liver volumetric study were carried out 
over the period of 3 weeks after transplantation of HLC 
Scope 
In this project, the team aimed to evaluate the toxicity and effects of HLC as the 
first step in developing CLEC as a treatment modality for liver failure. 16 adult 
pigs were chosen for this study and 50% hepatectomy was performed to create 
a liver insufficient animal model. After the surgery, the subjects will either 
receive a saline soaked collagen scaffold (control) or HLC soaked collagen 
scaffold (study) and were monitored periodically. At the end of 3 weeks, all 
subjects were sacrificed unless advised by the veterinarians for earlier 
termination.  
The respective investigations were carried out as highlighted in the objectives 
of this study and data was collected. Analysis of data, image processing as well 
as consultations with clinical experts were performed and reported in this report.   







The liver is the largest internal human organ and an average adult liver weights 
about 1,400 g. Based on external anatomical structure, the human liver can be 
divided into 4 lobes: Left, Right, Quadrate and Caudate respectively. French 
surgeon Couinaud proposed further segmenting the human liver into 8 portal 
territories based on its internal architecture [3]. Each segment has its own 
arterial supply, venous and biliary drainage, number in a clockwise manner, 
shown in Fig. The human liver is highly vascular and has a unique dual blood 
supply (about 1600 mL/min), up to 80% comes from the portal vein and the rest 
from the hepatic artery. 10-15% of the total body blood volume remains in the 
liver, an extremely high proportion compared to other internal organs [4, 5]. 
Porcine models are commonly used in experimental surgery due to their 
resemblances with the human morphology and size. Like the human liver, pig’s 
liver can be described as having 4 lobes and further divided into 8 surgical 
segments. The segmental nature of the pig liver acts as a good template for the 
investigation of liver surgery, transplantation and hepatic regeneration [6]. 
Liver physiology between the humans and pigs are highly similar too, owing to 
their respective microarchitectures. Hepatic lobules, the functional units of 
liver, were first described in pigs in 1664 (see Figure 1). In the human liver, 
these microscopic unit amount to over a million count and are approximately 
1mm wide. Hepatic lobules are primarily made up of the portal fields, 
hepatocytes sheets, sinusoids and the central veins (see Figure 2). 




Figure 1: Hepatic lobules on porcine liver surface. The porcine’s hepatic lobule is outlined by the 
connective tissue septum, allowing different lobules to be clearly visible on the laproscopy monitor. Image 
is taken during the hepatectomy procedure of ADD2 subject.   
 
 
Figure 2: Structure of the mammalian hepatic lobule. Left-to-right arrows show the flow of blood 
through the sinusoid while right-to-left arrow show the draining of bile through the portal field. Image 
adapted from [7]. 
 
The portal field contains the triad of tiny branches of the portal vein, hepatic 
artery and bile ductile, together with nerves and lymphatic vessels. The triad 
travel together within portal fields of adjacent lobules. The portal vein and 
hepatic artery deliver oxygenated blood with nutrients into the sinusoids. The 




exchange between the hepatocytes and surrounding blood sinusoids enables 
many metabolic processes to take place. Hepatocytes are polygonal epithelial 
cells and they are arranged in 2-D unicellular plates. These plates overlap and 
form complicated 3-D walls, seen in the lobules. Consequently, blood with 
detoxified substances and metabolic end products flows out of the sinusoids, 
into the central vein. The central vein ultimately reunites with the hepatic vein 
transporting these substances out of the liver. On the other hand, bile generated 
by hepatocytes travels in the opposite direction through bile canaliculi and 
drains into the bile ductules of the triad [4, 8].  
The liver lobule can be defined according to multiple perspectives and has 
constantly evolved over time as more findings are reported (see Figure 3). The 
classic hepatic lobule or central vein lobule, based on the structural appearance, 
resembles a hexagon with portal fields at the corners and the central vein is 
located in the center of the lobule. Blood flows in a centripetal direction while 
bile flows centrifugally towards the periphery. The portal vein lobule is based 
on the bile-formation characteristic of the liver. The portal field is located at the 
center while the central veins form the limiting points of the lobule. Blood flows 
from the center towards the periphery while bile flow in the opposite direction, 
produced in the surrounding hepatocyte plates.   
Recent findings show that hepatocytes are structurally heterogeneous based on 
their positions with respect to the portal vein. This leads to the more recent 
hepatic acinus model which takes into account the “zoning” nature of the 
hepatocytes. Zone 1 is the periportal region, closet to the portal vein lobule 
while Zone 3 is the perivenous region, closet to the central vein. Ultra-cellular 
structures in the hepatocytes also varies in different zones. Mitochondria and 
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the Golgi structures are more numerous in Zone 1 than in Zone 3. On the other 
hand, there is less smooth endoplasmic reticulum in Zone 1 compared to Zone 
3. Furthermore, cellular multiplication was shown to take place in the periportal 
region and subsequently migrates to the center, suggesting that hepatocytes are 
highly pluripotent cells.  
 
Figure 3: Different views on the basic unit of the liver. CV represents central vein, P represents portal 
field, blue arrow represents venous blood flow, red arrow represents arterial blood flow and green arrow 
represents bile flow. Image taken from [4]. 
 
Despite its simple architecture, the liver performs numerous vital biochemical 
processes, such as metabolism of oxidative energy, xenobiotics and bile 
formation, either continuously or in biological rhythms. To maintain 
homeostasis in the body, an intricate level of control is required. The zonation 
of the hepatic acinus model demonstrates how two physiologically opposite 
metabolic processes, gluconeogenesis and glycolysis, could be performed 
simultaneously by hepatocytes in the periportal and perivenous regions 
respectively. Various metabolic pathways are compartmentalized to speciﬁc 
regions along the hepatocyte plate and allows for differential expression of 




proteins across zones. The liver produces most of the circulating proteins, 
including the main blood plasma protein, albumin. The human liver synthesizes 
200mg of albumin per kg of body weight per day. [9, 10] 
 
Laboratory Diagnostics  
Being a critical organ of the body, it is clinically necessary to monitor and being 
a critical organ of the body, it is clinically necessary to monitor and quantify the 
functioning of the liver. Hepatocellular damage is typically assessed by 
measuring enzymes that were released into the blood through the damaged 
plasma membranes of the hepatocytes. The most frequently used indices are 
serum concentrations of aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT). These enzymes, which are involved in the pathways 
of gluconeogenesis, catalyse the enzymatic transfer of the α-amino group from 
the respective amino acid, aspartate or alanine, to α-ketoglutarate, yielding 
glutamate and, respectively, oxaloacetate or pyruvate. The enzyme levels are 
commonly determined in laboratories via spectrophotometry of the formation 
of NAD+, which correlates directly with the concentration of aminotransferase 
of the sample [11, 12].  
Aminotransferases in serum are usually elevated during hepatocellular injury of 
any cause and ALT value generally exceeds AST value due to the location of 
the different enzymes. ALT is localized exclusively in the cytosol of 
hepatocytes while majority of AST is found in the mitochondrial membrane. 
Only during cellular necrosis with associated destruction of mitochondria does 
the AST value exceeds that of ALT.  Hence, this constitutes the basis for the 
 Cord-stem Cell Application for Regeneration Enhancement in Porcine Model 
8 
 
DeRitis ratio (AST/ALT). It was suggested that a DeRitis ratio above 0.6 is 
associated with a poor outcome in cases of severe acute hepatitis while a ratio 
above >2 is indicative of alcoholic or malignant liver diseases.  
Lactate dehydrogenase (LDH) is another marker for hepatocellular damage. 
LDH is a cytoplasmic enzyme which catalyzes the reversible conversion of 
lactate to pyruvate, utilizing NAD+/NADH as a cofactor. It exists as five 
different isoenzymes and is found in almost all tissues in varying 
concentrations. Increased release of LDH from damaged, dying or 
metabolically deranged cells in any of these tissues may cause an elevated 
serum LDH concentration. Specifically, for the liver, marked elevation of serum 
LDH is indicative of liver metastases and obstructive jaundice. It is commonly 
measured using photometric assessment of the oxidation rate with NADH.  
The synthetic ability of the liver can also be assessed from certain plasma 
protein concentrations, such as albumin (ALB), produced selectively by the 
liver. ALB is a single, un-glycosylated polypeptide chain of 575 amino acids 
(molecular mass 69 kDa). It is synthesized exclusively by hepatocytes and has 
two principal functions in plasma: maintenance of osmotic pressure and 
transport of compounds through reversible binding. Binding with dyes, such as 
bromocresol green or bromocresol purple, in pH 4.15 is often used in 
laboratories to detect the concentrations of serum albumin. Due to its long half-
life (14 – 21 days), severe acute liver diseases only exhibit decreased ALB 
concentration during the later course. 




Another common synthetic assessment used is prothrombin time (PT). This test 
reflects the functional presence of factors involved in the blood clotting 
pathway, which are produced specifically by the liver. Sodium citrate is often 
used as anticoagulant and comes as premix in the blood sample collection tube. 
The result (in seconds) is determined from the time of the addition of calcium 
and tissue thromboplastin to the time of the clot formation. An extended time to 
clot formation is suggestive of impaired hepatocyte synthetic function. The 
International Normalized Ratio (INR) was devised to standardize PT results 
between manufacturers, due to variations in the type of factors used in 
performing the test.  
Weakening of the excretory functions of the liver can be indirectly assessed 
from increases in the plasma levels of compounds that are normally cleared by 
the liver and secreted in bile. Bilirubin, a yellow pigment, is an example of such 
compounds. A product from the breakdown of aged red blood cells, it exists in 
the body as either unconjugated or conjugated forms. Unconjugated bilirubin 
(IB) is insoluble in water and majority is found in serum. Hepatocytes uptake 
unconjugated bilirubin from the blood circulation and is where conjugation with 
glucuronic acid takes place. This renders the conjugated bilirubin (DB) water-
soluble and is secreted together with bile into the intestines and finally expelled 
with faeces.    
Spectrophotometric method is commonly used in laboratories to measure the 
concentration of serum bilirubin. Bilirubin reacts with diaotized sulfanilic acid 
to produce azo pigments. ‘Accelerator’ compounds, such as caffeine or ethanol, 
are added to hasten the reaction of IB, to produce the result of total bilirubin 
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concentration (TBIL). In a healthy person, none or low concentrations of 
conjugated bilirubin is found in the serum as they are removed via the biliary 
pathway. Conjugated hyper-bilirubinaemia is indicative of significant hepato-
biliary disease. On the other hand, unconjugated hyper-bilirubinaemia could 
suggest shunting around the liver of portal blood.  
Alkaline phosphatase (ALP) is a metabolic enzyme located in the cells, lining 
the biliary ducts of the liver. Elevated level of ALP is highly indicative of biliary 
obstruction or bile secretion dysfunction. The increase secretion of ALP into 
blood is stimulated by bile acids. ALP activity is assayed enzymatically, 
utilizing the hydrolysis of phosphate esters. 
There is no single biochemical method which provides a global statement on 
the hepatic function itself. It is often that these assessments are carried out and 
examined together to reveal typical patterns of different pathophysiological 
conditions, as well as the severity of the liver disease. Hence, health institutions 
utilize a series of mentioned assessments, known as hepatic panel or LFT to 
evaluate the patient’s liver condition. Shown in Figure 4 is a result slip of 
National University Hospital’s Liver Panel.   
 







Figure 4: Overview of general liver panel test. Image taken from National University Hospital. 
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Imaging and Histology of Liver  
Imaging the liver is just as important as its laboratory diagnostics. A computed 
tomography (CT) scan is a common imaging method to create pictures of cross-
sections of the liver. CT scan uses the attenuations of many finely focused X-
rays, which are subsequently measured by multiple detectors and converted to 
electrical signals. These values are then transmitted to a computer to calculate 
the absorption value of each image point and relaying it into a complex digital 
image.  A sequence of arterial, portal-venous and delayed phase imaging has 
been developed to display and differentiate between the hepatic arteries, portal 
and hepatic veins, and the hepatic parenchyma. This is known as the triple phase 
liver CT. Contrast agent, such as Omnipaque (iohexol), is introduced into the 
patient’s body rapidly via intravenous injection. The liver is subsequently 
scanned at specific time intervals to achieve the required multiphase images 
[13]. 
A group from I2R had recently developed a system to measure the liver volume 
through CT images. From the collected CT images, a rough 3D liver volume 
was automatically segmented using 3D mesh deformation-based method. A 
refinement step was subsequently introduced to eliminate the segmentation 
error by using a 3D post-editing tool, followed by mesh-volume conversion to 
determine the liver volume. According to a study by Nieheus et al., high 
correlation was discovered between CT-based and water displacement methods 
to measure liver volume. CT-based volumetric method was found to be 13% 
higher than water displacement volumetric measure. (p <0.0001). The factor 
leading to the difference between in-vivo CT volumetry and ex-vivo water 




displacement methods was due to blood perfusion of the liver in-vivo. It was 
recommended that a systematic difference of 13% has to be taken in account 
when dealing with these two methods [14-16]. 
The microscopic analysis of cells and tissue play in important role in today’s 
clinical diagnosis, commonly known as the field of Histology. The process of a 
typical histological assessment begins with the collection of tissue specimens. 
This can be done via biopsies, large organ resections or from cytological 
examinations. This is followed by tissue fixation for two purposes, to delay the 
decay process and to preserve the cellular architecture and composition for 
downstream analysis. Specimens are immersed in specific groups of chemicals, 
known as fixatives, for this purpose. Formalin is the most commonly used 
fixative due to its low cost and high degree of adaptability. Used in this study 
was 10% neutral buffered formalin, consisting of 3.7% formaldehyde in water 
and monosodium phosphate salts. Formaldehyde, in aqueous solution, forms 
methylene glycol. When specimens are immersed in formalin, they are rapidly 
penetrated by methylene glycol. Within the tissue, formaldehyde dissociates 
and cross-links with the various functional groups of biological 
macromolecules. The initial cross linking is completed within 48 hours after 
penetration and forms stable covalent cross linkages over time. It is known in 
the field, prolonged storage of specimens in formalin yield poor antigen and 
gives rise to false negative results.  
Tissue processing is recommended after 2 days of tissue fixation. Fixed tissue 
is dehydrated with alcohol and xylene and embedded with molten paraffin wax. 
The tissue forms a solid block after the wax cools. Devices known as 
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microtomes are used to cut the tissue block into sections of 3-5 µm thick. The 
section is placed on a glass slide, stained and lastly covered by a cover slip. The 
specimen is ready for histological examination [17, 18]. 
Diagnostic evaluation of tissue is largely based on a thorough examination of 
sections stained with hematoxylin and eosin (H&E). Hematoxylin is basic and 
binds to nuclear material that are acidic and negatively charged, staining them 
violet. On the other hand, eosin is acidic and binds to positively charged protein 
side chain, staining them pink. 
Other special stains may be required to identify features that are not easily seen 
on an H&E stain. This study additionally uses Masson’s trichrome (MT) stain, 
another common stain applied to liver specimens during clinical evaluations. 
The stain specifically highlights type I collagen fibers and imparts a blue colour 
to the fibers. It is useful in quantifying and staging the stage of liver fibrosis. 
Hepatocytes and cytoplasmic structures are stained pink while nuclei are stained 
dark red or black. 
The next stain used in this study was immunohistochemical staining (IHC). In 
any IHC examination, a particular antibody, known as the primary antibody, is 
used to identify the protein of interest, through a specific antigen-antibody 
reaction. Subsequently, an enzyme conjugated secondary antibody – which 
reacts specifically with the primary antibody – is introduced to the specimen. 
The conjugated enzyme catalyses a chromogenic reaction and produces a colour 
signal wherever the specific antigen–antibody reaction has taken place. These 
colour signals are observed under a light microscope [19, 20].  




Regeneration of Liver 
In healthy livers, hepatocytes remain quiescent, replication activity is low and 
matches the low prevalence of hepatocyte apoptosis observed clinically. During 
an injury, the liver has enormous capacity to regenerate, where reconstitution of 
functional liver mass is completed within weeks of partial hepatectomy 
(surgical removal of the liver). As such, the two-third hepatectomy model of 
mice and rats, reflecting acute injury to the liver, is commonly used for the study 
of regenerative molecular medicine.  
Regeneration of the liver can largely be attributed to enhanced hepatocyte 
proliferation. In partial hepatectomy, DNA synthesis and the mitotic index are 
enhanced in the remaining liver in relation to the removal of tissue volume. 
Animal studies demonstrated that DNA synthesis in mature hepatocytes begins 
24 hours after partial hepatectomy and the hepatocyte mitotic index increases to 
as high as 13-fold within the initial 72 hours [21, 22]. 
In cases of chronic disease or severe acute injury to the liver, proliferation of 
hepatocytes is either impaired or insufficient to regenerate liver volume 
adequately. Differentiation and multiplication of liver stem cells come into play 
to replace the damaged hepatocytes. A stem cell is an undifferentiated cell 
capable of self-renewal and generating one or more types of specialized cells. 
Characterized by its histology, oval cells are adult liver stem cells that reside in 
the small terminal bile ducts. Oval cells are shown to be the progenitor for 
hepatocytes and bile duct cells. Oval cell activation is observed in majority of 
chronic human liver diseases and the degree of progenitor cell activation 
correlates with the amount of inflammation and damage.  
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Several recent studies are exploring how oval cells can be used as a treatment 
for liver diseases. Sources of oval cells studied included bone marrow cells and 
re-programming of hepatocytes. However, oval cells were found to be directly 
associated in the histogensis of hepatocellular carcinoma (HCC) and its markers 
were associated with worse prognosis and more recurrences after surgical 
treatment. It is widely accepted in the field that more needs to be understood 
before oval cells can be used as a form of stem cell therapy [23-26]. 
A well-known mitogenic signal in liver regeneration is hepatocyte growth factor 
(HGF). HGF has been shown to increase 10 to 20 folds in serum after partial 
hepatectomy. HGF is consumed during the first 3 hours of PH and new HGF 
are synthesize within 48 hours. In cell cultures, HGF is observed to cause strong 
mitogenic responses and clonal expansion of hepatocytes. It is produced by 
other organs, such as the lung and spleen, though the liver is the largest 
contributor. Its receptor, c-met, is expressed in most cells and facilitates all the 
effects of HGF. Animal studies also show that the HGF/c-met signalling 
pathway is irreplaceable in the process of liver regeneration. C-met absent mice 
were more vulnerable to hepatectomy while surviving mice displayed numerous 
areas of necrosis and signs of chronic liver damage.  
There is no one single factor the mediates the progression of liver regeneration. 
Other signals include interleukin-6 and epidermal growth factor. Termination 
of liver regeneration is also an organized process. Regenerated liver volume 
typically falls within 5% to 10% of the original volume before hepatectomy. 
TGF-1 is a known suppressor of hepatocyte proliferation. Its expression 
increases within 5 hours after partial hepatectomy and acts in an antagonistic 




action against HGF to control the rate of restoration, where it remains elevated 
in serum until the end of liver regeneration [27-31]. 
Fibrosis and Cirrhosis  
Despite having multiple growth signals and pathways for inducing liver 
restoration, the regenerative capacity of liver cells is limited. This is observed 
through chronic liver diseases in which hepatocytes do not replicate normally, 
significantly activating oval cells as a result. A plausible explanation for the 
impaired hepatocyte regeneration is the shortening of telomeres. Telomeres are 
simple tandem nucleotide repeats that are located at each end of chromosomes. 
They do not encode for any gene product, but serves to cap and protect the 
chromosomal ends from DNA damage. Due to the limitation of DNA 
polymerase, telomeres shorten by 50–100 base pairs after each cycle of cell 
division in human cells. Upon reaching a critical short length of telomeres, the 
cell undergoes a permanent cell cycle arrest, known as senescence.  Telomerase 
is an enzyme that serves to synthesize new telomere sequences but remains 
active only in immature germ cells and certain stem and progenitor cells in 
adults. despite the reactivation of telomerase in chronic liver diseases, 
accelerated telomere shortening is still observed, surpassing the synthesis of 
new base pairs at the ends of the chromosomes.  
Recent literature shows that healthy livers contain a high percentage of 
hepatocytes with multiple sets of chromosome (polyploidy), reflecting the 
complexity and adaptability of the liver. Furthermore, hepatocytes enlarge in 
cell size (hypertrophy) as the first step of compensatory response after partial 
hepatectomy. On the other hand, polypoidal and enlarged hepatocytes are found 
to be significantly higher in numbers in chronic liver diseases. Enlarged 
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hepatocytes lead to the production of portal hypertension, a symptom 
commonly associated with chronic liver disease. This highlights the role of 
telomeres in hepatocyte regeneration as de-protection of telomeres has shown 
to lead to higher rates of polyploidization and DNA replication without cell 
division contributes to cellular hypertrophy [21, 32-35]. 
Hepatic fibrosis is often the outcome of prolonged impaired regeneration. This 
is characterized by the deposition of excessive extracellular matrix as part of the 
regenerative response, due to the hyper-activation of the hepatic stellate cells. 
Stellate cells are activated upon injury to the liver and transdifferentiate into 
myofibroblast-like cells. These cells deposit extracellular collagen, forming 
temporary scars to contract the injured sites. They also promote regeneration 
and angiogenesis by secreting cytokines and growth factors. After healing is 
complete, apoptosis takes over to remove the temporary scars.  However, in 
chronic liver diseases, hepatic stellate cells are activated more rapidly and 
aggressively, resulting in widespread scar formation [36-38]. 
With the presence of iterative damage, such as chronic hepatitis or alcoholic 
abuse, the fibrotic process progresses and worsens. Nodule formations are 
resulted and eventually, leads to late-stage scarring, known as cirrhosis. 
Cirrhosis is characterized as the loss of lobular structure and internal liver 
vascular supply is compromised. It is highly debated in the field regarding the 
reversal of cirrhosis. Clinical cases and animal studies has shown the regression 
of fibrosis after the cause of injury is removed. However, the loss of lobular 
architecture has shown to be permanent in cirrhosis despite improving hepatic 
functions after intervention [22, 39-43]. 




The only current effective treatment for patients with end-stage cirrhosis is a 
liver transplant. However, not all patients are suitable for liver transplantation. 
Essentially, the patient must be able to survive longer with transplantation 
compared to without transplantation. Due to the limited supply of donors, 
several grading models were created to prioritize recipients and allocation of 
donor organs. Compatibility of blood groups, quality and size of donor liver are 
additional considerations as well. After which, long-term immunosuppressive 
regimes are administered to prevent transplant rejection. These challenges are 
pushing clinicians and researchers to search for alternate therapies for chronic 
liver diseases [44-47]. 
Alternate Therapies for Liver Diseases 
Besides transplanting the donor liver, clinicians had also tried transplanting with 
hepatocytes, isolated from livers that are unused or deemed unsuitable for 
transplantation. Hepatocyte transplantation in humans has met with varied 
success, largely dependent on the disease state. Nevertheless, donor availability 
is the crucial limiting factor and stem cell-derived hepatocytes are being 
investigated for this cause [48-50]. 
According to a report conducted by EuroStemCell on the trend of stem cell 
research, it was estimated that there were close to 100,000 active stem cell 
researchers globally in 2012. 47% of stem cell publications were linked to 
regenerative medicine. A group of researchers attempted to treat liver fibrosis 
in mice using mesenchymal stem cells (MSC) derived from bone marrow. 
However, bone marrow as a source of stem cells has its disadvantages. In 
clinical bone marrow transplant, the donor is often put under general 
anaesthesia, posing some form of risks to the donor. This had led other 
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researchers to look for alternate sources of MSC, such as Wharton’s Jelly, from 
the umbilical cord, which is often discarded after giving birth.  
While results using MSC are promising, the development to hepatocytes are 
highly controversial. Mesenchymal cells are non-polarized cells, capable of 
moving as individual cells, lacking intercellular connections. Epithelial cells, 
like hepatocytes, are adherent cells that attach to each other, forming coherent 
layers exhibiting apical-basal polarity. It is believed that MSC undergo 
mesenchymal to epithelial transition and form hepatocytes in treating the injury, 
which is not yet well understood [51-54]. 
Cord Lining Epithelial Cells (CLEC) 
The dilemmas associated with the ethical and social issues of potential stem cell 
therapies must be thoroughly examined to ensure that science remains as the 
vehicle for hope and not harm. Our research ultimately aims to use HLC as an 
alternate therapy for liver diseases by enhancing liver regeneration. This can be 
achieved via two ways, through trophic factors that repair cellular damage and, 
replacing damaged hepatocytes and its functions.  
As mentioned above, the umbilical cord is an attractive source of stem cells, as 
it is usually discarded as bio-waste accompanying the delivery of a new-born. 
The absence of risks to either mother or child makes it ethically acceptable. 
Furthermore, the supply of umbilical cords is highly sustainable. CLEC was 
discovered by the group led by Phan in 2003 when they cultured umbilical cord 
amniotic membrane in modified keratinocyte medium [55]. It was estimated 
that a single umbilical cord could yield 6 billion CLEC at passage 1, far 




exceeding the MSC that could be derived from bone marrow, cord blood, and 
adipose tissue. 
CLEC possess properties of both epithelial cells and embryonic stem cells. The 
cells were tested positive for MUCIN1, whose function is to protect the 
epithelium by binding to pathogens; CD151, involved in epithelial cell-to-cell 
adhesion; p63, an adult epithelial stem cell marker and CK7, CK14 and CK19 
in varying degrees. Furthermore, cells were positive to several embryonic stem 
cell markers, such as Oct-4, Nanog, ring-exported protein-1 (REX-1), SOX-2, 
telomerase reverse transcriptase (TERT), and SSEA-4.  
This had led Phan and team to further explore the clinical applications of CLEC. 
CLEC was found to closely resemble primary neonatal epidermal keratinocytes, 
showing its potential in tissue-engineered skin grafts [56]. The team 
investigated the transplantation potential of CLEC in immuno-competent mice 
[57]. CLEC were maintained for extended periods compared to human 
epithelial cells serving as control (see Figure 5).  
In another study, CLEC was seeded on human amniotic membrane and 
transplanted onto limbal stem cell deficient rabbits [58]. The tissue-engineered 
cell sheets successfully regenerated the damaged cornea surface and 
histological examination revealed that the cellular organization in the 
transplanted eyes resembled that of normal healthy cornea epithelium (see 
Figure 6). Due to its multi-potency and immunosuppressive qualities, CLEC 
was also studied as potential bio-implants for safe and long-term secretion of 
anti-hemophilic factor in hemophilic patients [59].  
 




Figure 5: CLEC surviving in xeno-transplant host up to 2 weeks. CLECs and keratinocytes were 
transfected to express DsRed2 and eGFP respectively under fluorescent microscopy.  At 14 days after 
transplantation, red fluorescence indicates the presence of CLECs while green fluorescence of normal 
human keratinocytes was not detected. Image taken from [57]. 
 
This study initially started out looking at alternative sources for in-vitro drug 
metabolism model. HLC were differentiated from CLEC to serve as a novel in-
vitro drug biotransformation study model [60]. HLC were found to develop 
morphological changes, glycogen storage abilities and metabolic capabilities, 
such as albumin production and cytochrome P450 expression. Other studies had 
suggested culturing isolated hepatocytes on extracellular matrix such as 
collagen, improved hepatocyte maturation and functions [61, 62]. 
For non-embryonic stem cells, CLEC have shown to overcome the pre-existing 
difficulties inherent to other stem cells, like MSC harvested from bone marrow 
and Wharton’s Jelly. Umbilical cord lining offers a realistic, practical and 
affordable alternative source of stem cells for tissue repair and regeneration.  
 
 





Figure 6: Effects of transplanted CLEC on rabbits’ corneal surface. (a & d) Damaged corneal with 
CLEC transplanted showed little opacity after 4 weeks and no opacity after 10 weeks. (b & e) Control 
membrane transplanted eye showed significant opacity in cornea after 4 weeks, with reduced opacity after 
10 weeks. (c & f) Eye with no transplant eyes exhibited opacity and neovascularization in cornea after 4 
and 10 weeks respectively. (g) H&E staining showed regular smooth corneal epithelium for CLEC 
transplanted eye. (h) Normal structure of un-treated corneal epithelium. (i) Thick corneal epithelium with 
some infiltrating cells for eye with no transplant. (j) Irregular corneal epithelium with many infiltrating 
cells in stroma for control membrane transplanted eye. Bar is 100 μm in length and image taken from [58]. 
 





Source of CLEC 
Human umbilical cords were collected with informed consent of the mothers 
after normal deliveries. The Wharton’s jelly and blood vessels were separated 
from the umbilical cord amniotic membrane by dissection. The isolated 
umbilical cord lining was cut into small pieces and explanted onto tissue culture 
dishes. The umbilical cord amniotic membrane was isolated by dissection, and 
explanted onto tissue culture dishes with proprietary medium, PTTe1, made up 
of Medium 171 supplemented with 2.5% v/v FBS, 50 µg/mL insulin-like 
growth factor-1, 50 µg/mL platelet-derived growth factor-BB, 5 µg/mL 
transforming growth factor-b1, and 5 mg/mL insulin.  
Low passages (1 or 2) of CLEC were selected for single-cell cloning. Colonies 
formed from single cells were monitored for 12 days and tested for hepatic stem 
cells makers. A small portion of cells were tested using immuno-staining assays 
for AFP, CK19, CK18 and Albumin. Cell colonies with high expression of 
hepatic stem cell markers of 60% and above were chosen for hepatogenesis.  
Hepatogenesis 
The chosen cell colonies were plated at a density of 5,000 cells/cm2 and cultured 
at 37ºC in an atmosphere of 95% air and 5% carbon dioxide. Upon reaching 
confluency at passage 3 or 4, the PTTe1 medium was replaced with hepatocyte 
culture medium (HCM™ Bulletkit®, Lonza). The CLEC colonies were cultured 
in HCM for 14 days, followed by hepatocyte maintenance medium (HMM™, 
Lonza) for another 14 days to differentiate into HLC. The media was refreshed 
every 2 to 3 days.   




Liver Insufficient Porcine Models 
50% left hepatectomy procedure – removal of 2 left most liver lobes – were 
performed on adult porcine to create a liver insufficiency animal model. 16 
Yorkshire-Dutch Landrace pigs, with a mean weight of 40.5 kg on day of 
surgery, were initially selected for this study. All pigs were tranquilized by 
intramuscular injection of ketamine (1 mg/kg). General anaesthesia was 
subsequently induced using 5% isoflurane and maintained at 3% isoflurane until 
the entire surgery was completed.  
The pigs were placed in supine position and the abdomen opened through a 
subcostal incision extending from the right anterior axillary line to the left mid-
axillary line, plus a midline incision from 2 cm above the xiphisternum to the 
transverse incision. Surgical tools were inserted into the body via laparoscopic 
ports (see Figure 7). The liver was mobilized by division of peritoneal 
reflections to the diaphragm and division of the falciform ligament. 
Subsequently, the left triangular ligament and the lesser omentum were divided 
to completely mobilize the left liver lobes. The parenchyma was lastly divided 
after control of inflow and outflow to each lobe.  
Novel Stem Cell Delivery Method 
After the two lobes were resected and removed, 2 pieces of 50 x 50 mm collagen 
scaffold (HealiAid® Collagen Wound Dressing, Maxigen) were directly 
applied on the cut liver surface. Figure 8 shows how the scaffold was applied. 




Figure 7: Setup for hepatectomy on porcine subject. Insertion of various laparoscopic ports and 
endoscope on ADD2 subject. Image taken in CM opertating theatre.   
 
 
Figure 8: Application of collagen scaffolds onto resected liver surface. Collagen scaffolds were 








Prior to application, the collagen scaffold was soaked for 5 minutes in either: 
a. 30 ml Normal saline solution (0.9% NaCl). Subjects receiving such 
scaffold were treated as the control arm. Or, 
b. 30 ml HLC solution (see Figure 9). On the day of the surgery, the HLC 
colony were gently detached from the tissue culture surface with cell 
scrapers and transported to the operating room. It was estimated that 10 
million HLCs were transferred into solution. Subjects receiving such 
scaffold were treated as the study arm. 
After soaking, 10 x 10 mm of scaffold were removed and fixed in 10% neutral 
buffered formalin solution for histological characterization.  
 
Figure 9: Soaking of collagen scaffolds in its respective solution. Collagen scaffolds were soaked for 5 
minutes in either saline or HLC solution on a sterile container. This was performed just before the 
application of the collagen scaffolds onto the resected surface.     
 
The remaining respective solution were dispensed directly over the resection 
site, after the collagen scaffolds were applied on the liver surface, using a 20 ml 
syringe, as shown in Figure 10. 




Figure 10: HLC solution in a 20 ml syringe. Remaining solution were extracted with the syringe and 
dispensed directly over the scaffolds, after being positioned on the resected surface.  
 
Lastly, the abdominal muscles and rectus sheath were closed with 1-0 PDS 
continuous suture, followed by closing of the skin with subcuticular 4-0 
Monocryl. A portal catheter was inserted permanently into the external jugular 
vein to allow frequent blood collection. Anaesthesia was discontinued and 
considered completion of surgery. All procedures followed aseptic precautions 
and were done under the approval of Institutional Animal Care and Use 
Committee (IACUC).  
Post-operative Care 
The pigs were housed in individual pens in NUS Comparative Medicine (CM) 
Vivarium, maintained at 25ºC and ambient humidity, over a post-operative 
observation period of 21 days. For the first 7 days, the pig was given analgesic 
(buprenorphine) and antibiotics (enrofloxacin, amoxicillin, clavulanic acid and 
carprofen) to reduce localised pain and inflammation. The portal catheter was 




flushed with 1% heparin w/ normal saline solution every other day for 
subsequent weeks to prevent deep vein thrombosis.  
Blood Examination 
10 ml venous blood were drawn from the subjects after the surgery ended (Post-
op), day 1 after surgery (POD1), day 2 after surgery (POD2), day 4 after surgery 
(POD4), day 6 after surgery (POD6), day 8 after surgery (POD8), day 15 after 
surgery (POD15) and day 21 after surgery (POD21) before euthanasia.   
The blood was sent to National University Hospital and examined for PT, INR, 
ALB, TBIL, DB, IB, AST, ALT, ALP and LDH. The data was subsequently 
collected and tabulated respectively.  
CT and Liver Volumetric Study 
CT scans of the liver were performed in NUS CM Imaging Facility, before the 
hepatectomy (Pre-op), Post-op, POD8 and POD15. The subjects were under 
general anaesthesia throughout the scans. Triple phase liver CT protocol was 
performed.  
Images from contrast-enhanced portal venous phase were extracted and sent to 
I2R for data processing. The liver volume was determined and tabulated 
respectively. On POD21, after the pig was euthanized via pentobarbital (150 
mg/kg), the liver (without the gallbladder) was harvested and its volume 
measured via water displacement method. The measured volume was increased 
13% to account for blood perfusion compared to CT-determined measurements. 
The results were tabulated respectively.  




On POD8 and POD15, CT-guided core needle biopsy was performed 
respectively, after the completion of the CT scan. The procedure was carried 
out by CM veterinarian, using a 16G 15 cm long percutaneous biopsy 
instrument (Temno Evolution®, Carefusion). The subject was placed in left 
lateral recumbancy and the biopsy needle was inserted between the right lower 
ribs. 40 mm3 core liver tissue was removed from the subject. CT images were 
referenced to prevent injury to major vessels. The core tissue was then sent for 
fixation in 10% neutral buffered formalin solution. 
On POD21, after water displacement volume measurement, the site where the 
collagen scaffolds were placed and a peripheral site away from the collagen 
scaffold (yellow circles in Figure 11), were removed from the rest of the liver 
via a #10 scalpel blade and immersed in 10% neutral buffered formalin solution 
for fixation. 
Tissue fixation was carried out for a minimum of 48 hours before sending to 
A*STAR Advanced Molecular Pathology Laboratory for automated tissue 
processing. This included processing fixed tissue into paraffin-embedded 
blocks, sectioning blocks into 5 µm thick samples and placing samples onto 
glass slides. For every block, one slide of H&E stained and one slide of MT 
stained slide were requested.  
Anti-Human Nuclei Staining 
Anti-nuclei human antibody (Merck Millipore, MAB1281) was used as the 
primary antibody. IHC staining was carried out on selected paraffin sections, 




according to protocol attached in Appendix A. Micrographs were taken and 
analysed respectively.  
 
 
Figure 11: Excised liver after subject’s euthanasia.  Excised liver was used in volumetric measurement 
and selected sites (circled in yellow) were removed and sent for hisotogical examinations. The partially 









Subject Profiles and Outcomes 
Due to the complexity in performing the 50% hepatectomy procedure on 
porcine models, only 11 out of 16 pigs (68.8%) were able to be transplanted 
with the respective collagen scaffolds. The remaining pigs suffered mortality 
amidst the surgery due to uncontrolled intraoperative blood loss. These pigs 
were omitted from the analysis of this study. Table 1 shows the profile and 
outcome of the 11 pigs that were transplanted with collagen scaffolds. 
Table 1: Overview of subjects’ details and post-operative survival. 
Subject 
Name 










CARE9 496089 M x 43.1 
40.0 
21 
CARE12 10000 M x 42.0 21 
ADD2 1096 F x 34.0 21 
ADD3 1098 F x 41.0 16 
CARE10 496090 M  38.0 
40.8 
21 
CARE11 496088 M  50.4 21 
CARE14 9999 M  41.8 15 
ADD4 7006 F  39.0 21 
ADD6 0069 F  42.6 21 
ADD7 1123 F  42.0 21 
ADD9 1163 F  32.0 21 
 
Both sexes were equally represented in both treatment groups while the weight 
difference between the two groups on the day of the surgery was 0.8 kg (2%). 
One subject from the control group and the study group suffered from ascites 
and were euthanized on post-operative day 16 and day 15 respectively. CM 
veterinarians attributed the cause to be intestinal adhesion and obstruction. All 
other subjects were euthanized at study end point of post-operative day 21.  
 





To show statistical differences between the two different groups with a large 
enough effect size and statistical power, a sample size of 60 porcine models is 
required with 30 in each group. The calculation is shown in Figure 12. This initial 
study serves as an abridgement to the larger sample size study and assumes that 
the samples drawn are from the same intended porcine population.  
 
Figure 12: Graph of sample size calculation. A sample size of 60 is required for 85% statistical power 
and 0.79 effect size.  





Figure 13: Graph of DeRitis ratio for 21 days after hepatectomy. Comparison of average DeRitis ratio 
between control and study group. Error bars represents one standard error. Raw data is found in Appendix 
B.  
 
Figure 13 shows the average DeRitis ratio of both groups for 21 days after the 
surgical procedure. Both groups had elevated DeRitis ratio after hepatectomy, 
with the peak ratio taking place on the subsequent day of surgery. The ratio of 
both groups dropped significantly and plateaued after post-operative day 4 to 
post-operative day 21. Performing a two sampled t-test with unequal variances, 
means of both groups were found not to be statistically significant (p >0.05). 
DeRitis ratio is used to indicate the extent of cellular necrosis and how fast the 
liver recovers from the fall of the ratio values. Hence, it is observed that both 
groups started liver recovery after post-operative day 4 with no statistically 























Prothrombin Clotting Time 
 
Figure 14: Graph of prothrombin clotting time for 21 days after hepatectomy. Comparison of average 
clotting time between control and study group. Error bars represents one standard error. Raw data is found 
in Appendix B. 
 
Figure 14 shows the average prothrombin clotting time of both groups for 21 
days after the surgical procedure. Both groups had peak clotting time at the 
subsequent day of surgery (>14 s) and the clotting time for both groups fall and 
stay within the range of 12.5 -13.5 seconds up to post-operative day 21. 
Performing a two sampled t-test with unequal variances, means of both groups 
were found not to be statistically significant (p >0.05). Prothrombin clotting 
time is used to indicate the synthetic capability of the liver. With approximately 
50% of the liver volume removed, the synthetic function of the liver is expected 
to be impaired. This is shown in the peak value at POD1 for both groups. 
However, this quickly drops for both groups with no statistically significant 
difference between both groups. Furthermore, suggesting that 50% hepatectomy 
may not be a damage severe enough to impair the synthetic capabilities of the 
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Serum ALP Concentration 
 
Figure 15: Graph of serum ALP concentration for 21 days after hepatectomy. Comparison of average 
serum ALP concentration between control and study group. Error bars represents one standard error. Raw 
data is found in Appendix B. 
 
Figure 15 shows the average serum ALP concentration of both groups for 21 
days after the surgical procedure. Both groups had elevated ALP concentration 
after hepatectomy, with the peak ratio taking place on the subsequent day of 
surgery. The ALP concentration continued to fall for both groups throughout 
the post-operative 21 days. Performing a two sampled t-test with unequal 
variances, means of both groups were found not to be statistically significant (p 
>0.05). Serum ALP concentration is used to indicate the extent of biliary 
dysfunction or obstruction. Therefore, it is observed that both groups had 
impaired biliary function due to the hepatectomy procedure and continued to 
recover from the damage through the 3 weeks after the surgery with no 



































Liver Volumetry  
 
Figure 16: Graph of liver volume before and 21 days after hepatectomy. Comparison of average liver 
volume (% of pre-Op volume) between control and study group. Error bars represents one standard error. 
Raw data is found in Appendix C. 
 
Figure 16 shows the average liver volume percentage of both groups as 
compared to the pre-operative liver volume for 21 days after the surgical 
procedure. With the removal of two left most liver lobes, approximately 42% of 
liver volume was excised from the subjects. By the end of the post-operative 
first week, approximately 46% of liver volume was regenerated for both groups. 
The liver of both groups then slowly adjusted to the pre-op liver volume till the 
end of post-operative day 21. Performing a two sampled t-test with unequal 
variances, means of both groups were found not to be statistically significant (p 
>0.05).  Liver mass reconstitution is an indicator on the rate of regeneration of 
the liver. Hence, it is observed that there is no statistically significant difference 































Before the application of the collagen scaffold onto the resected sites, a 10 mm 
x 10 mm of scaffold after soaking with HLC were removed for histological 
characterization. Figure 17 shows the wavy thread-like structure of the collagen 
scaffold structure while Figure 18 shows the epithelial cell characteristics of 
HLC. Despite the porous structure of the collagen scaffold, it was also observed 
in Figure 20 that HLC only penetrated the surface of the scaffold superficially. 
No HLC was found in the inner layers of the collagen scaffold.  
 
 
Figure 17: H&E staining of collagen scaffold with HLC. Scaffold was soaked in HLC for 5 minutes. 
The collagen scaffold was observed to have wavy and random threadlike structures. Observed using 4x 
objective lens. 





Figure 18: H&E staining of HLC displaying epithelial cell characteristics. Scaffold was soaked in 
HLC for 5 minutes. The squamous structure of HLC is clearly visible, located at the surface of the scaffold. 
Observed using 4x objective lens. 
 
 
Figure 19: H&E staining of HLC before implantation. Scaffold was soaked in HLC for 5 minutes. The 
squamous structure of HLC is clearly visible, located at the surface of the scaffold. Observed using 10x 
objective lens. 




Figure 20: H&E staining on inner layers of scaffold. Scaffold was soaked in HLC for 5 minutes. No 
HLC was observed in the inner layers of scaffold, suggesting that HLC only penetrated the collagen 
scaffold superficially. Observed using 4x objective lens. 
 
Masson’s Trichrome Staining 
To understand how the collagen scaffold is being absorbed by the porcine liver 
after post-operative 21 days, MT staining is performed on the scaffold-liver or 
transplant interface. The stain specifically highlights collagen fibers and imparts 
a dark blue colour to the collagen scaffold fibers. Figure 21 shows the 
absorption of the collage scaffold into the transplant interface of a subject from 
the control group. Figure 22 shows the absorption of the collage scaffold into 
the transplant interface of a subject from the study group. Furthermore, this 
staining also allow for the localization of human antigens during IHC staining. 
 





Figure 21: MT staining of collagen scaffold after POD21 in control subject. Section was removed 
from the scaffold-liver interface in subject ADD2. It was observed that the scaffold was being absorbed 
into the fibrous tissue of the liver as part of the regenerative process. Observed using 4x objective lens. 
 
  
Figure 22: MT staining of collagen scaffold after POD21 in study subject. Section was removed from 
the scaffold-liver interface in subject ADD4. It was observed that the scaffold was being absorbed into the 
fibrous tissue of the liver as part of the regenerative process. Observed using 4x objective lens. 




Figure 23: MT staining of scaffold after POD21 in study subject (magnified). Section was removed 
from the scaffold-liver interface in subject ADD4. It was observed that the scaffold was being absorbed 
into the fibrous tissue of the liver as part of the regenerative process. Observed using 10x objective lens. 
 
Transplant Interface Observations 
The interface between the collagen scaffold and resection margin surface was 
also studied for both groups. Interfaces of both groups, after post-operative 3 
weeks, showed minimal and non-specific reactions. No signs of fatty changes 
or significant cellular rejection were observed adjacent the interfaces of both 
groups. Figure 24 shows the interface from a control subject while Figure 26 
shows that of a study subject. Healthy liver lobules were observed next to the 
regenerating fibrous tissue for both control and study groups, shown in Figure 
25 and Figure 27 respectively.   
 





Figure 24: H&E staining of transplant interface after POD21 in control subject. Section was removed 
from the scaffold-liver interface in subject ADD2. It was observed that the scaffold (extreme right) was 
being absorbed into the fibrous tissue of the liver as part of the regenerative process. No signs of specific 
or significant reactions were detected. Observed using 4x objective lens. 
 
 
Figure 25: H&E stained lobules adjacent transplant interface of control subject. Section was removed 
from the scaffold-liver interface in subject ADD2. Healthy lobular structures were seen next to the 
regenerating fibrous tissue. No signs of fatty changes or cellular rejections were detected. Observed using 
4x objective lens. 




Figure 26: H&E staining of transplant interface after POD21 in study subject. Section was removed 
from the scaffold-liver interface in subject ADD7. It was observed that the scaffold (extreme right) was 
being absorbed into the fibrous tissue of the liver as part of the regenerative process. No signs of specific 
or significant reactions were detected. Observed using 4x objective lens. 
 
 
Figure 27: H&E stained lobules adjacent transplant interface of study subject. Section was removed 
from the scaffold-liver interface in subject ADD7. Healthy lobular structures were seen next to the 
regenerating fibrous tissue. No signs of fatty changes or cellular rejections were detected. Observed using 
4x objective lens.  




Peripheral Liver Histology  
To investigate the overall condition of the liver, histological samples, located 
peripherally from the transplant interface were obtained and studied. Core tissue 
biopsy were performed on post-operative week 1 (see Figure 28) and week 2 
(see Figure 29) to observe if any reactions were taking place due to the 
transplanted HLC. Week 3 samples (see Figure 30) were retrieved from the 
excised liver after euthanasia. Healthy lobular structures were seen and no signs 
of fatty changes or cellular rejections were detected, throughout the post-
operative 3 weeks, in the peripheral locations. Figure 31 was obtained from the 
excised liver lobe after hepatectomy and used as a pre-op reference.  
  
 
Figure 28: H&E stained liver biopsy on POD8 in study subject. Tissue was removed from subject 
ADD6’s right liver lobe via core tissue biopsy. Healthy lobular structures are visible and no signs of fatty 
changes or cellular rejections were detected. Observed using 4x objective lens.  
 
 




Figure 29: H&E stained liver biopsy on POD15 in study subject. Tissue was removed from subject 
ADD6’s right liver lobe via core tissue biopsy. Healthy lobular structures are visible and no signs of fatty 
changes or cellular rejections were detected. Observed using 4x objective lens. 
 
 
Figure 30: H&E stained liver sample on POD21 in study subject. Tissue was removed from subject 
ADD6’s excised right liver lobe after euthanasia. Healthy lobular structures are visible and no signs of 
fatty changes or cellular rejections were detected. Observed using 4x objective lens. 





Figure 31: H&E stained pre-op liver sample from study subject. Tissue was removed from subject 
ADD6’s excised left liver lobe after hepatectomy procedure. Post-operative histological samples’ 
conditions were found comparable to that of pre-op sample, suggesting the insignificant toxicity of 
transplanted HLC. Observed using 4x objective lens. 
 
Human Antigen Staining 
From previous studies conducted, CLEC was found to possess 
immunosuppressive qualities and was able to survive in immunologically-
competent hosts. Such characteristics for HLC, on the other hand, was still 
unclear. Staining for human antigens, allowed the team to check the viability of 
HLC 3 weeks after transplantation in a xeno-transplanted host. Bright field IHC 
was first performed on the scaffold with HLC for characterisation (see Figure 
33). Human antigen staining was then carried out on paraffin sections from the 
study group. Analysis were compared with MT slides for scaffold localization. 
Figure 35 shows evidence of surviving HLC 3 weeks’ post-transplantation. 
Figure 36 shows a porcine hepatic lobule from the same sample as negative 
control reference.   




Figure 32: IHC staining of collagen scaffold with HLC. Scaffold was soaked in HLC for 5 minutes. 
HLC is clearly visible with its stained cytoplasm and nucleus. Observed using 4x objective lens. 
 
 
Figure 33: IHC staining of collagen scaffold with HLC (magnified). Scaffold was soaked in HLC for 
5 minutes. HLC cytoplasm is stained dark with black nuclear staining. Observed using 40x objective lens. 
 





Figure 34: IHC staining of collagen scaffold after POD21 in study subject. Section was removed from 
subject ADD4 at same location as Figure 23. Dark cytoplasm is observed at collagen scaffold. Observed 
using 20x objective lens. 
 
 
Figure 35: IHC staining of HLC after POD21 in study subject. Section was removed from subject 
ADD4 at same location as Figure 23. Dark cytoplasm is observed at collagen scaffold and black nuclear 
staining. Longitudinal cellular nuclear structure is comparable to that of Figure 33, suggesting evidence of 
HLC viability after 3 weeks’ post transplantation. Observed using 40x objective lens. 




Figure 36: IHC staining of porcine lobule after POD21 in study subject. Section was removed from 
subject ADD4. Same paraffin section as Figure 34. Black nuclear staining is not detected. Observed using 
10x objective lens. 
 
 
Figure 37: IHC staining of central vein after POD21 in study subject (magnified). Section was 
removed from subject ADD4. Same paraffin section as Figure 34. Black nuclear staining is not detected. 
Circular nuclear structure suggestive of porcine descent. Observed using 40x objective lens. 






Safety of Transplanted HLC 
The first objective of this study was to evaluate the toxicity of transplanting 
HLC into a xeno-transplanted host. Starting from the LFT, no statistically 
significant differences were found between the control and study group in the 
aspects of cellular damage, synthetic function, biliary function and mass 
regeneration of the liver. All but one subject in the study group survived till 
post-operative 3 weeks, with intestinal adhesion as the likely early euthanasia 
reason. The transplant interfaces were evaluated and no signs of cellular 
rejections were observed for both groups. Healthy lobular structures were seen 
adjacent to the transplant interfaces. Histology performed on peripheral liver 
sites for post-operative week 1, week 2 and week 3 showed similar conditions 
as that of pre-transplantation of HLC.  
However, few factors were not considered in this study which may have 
significant effects on the outcomes. Firstly, intraoperative blood loss during the 
50% hepatectomy procedure was not considered. Clinical studies had shown 
that intraoperative blood loss has a negative impact on postoperative outcome 
for patients [63]. Similarly, the intraoperative blood loss for both groups may 
had been different, leading to a significant difference in the outcomes. Secondly, 
the percentage of surviving HLC after post-operative 3 weeks was not 
considered as well. Toxic effects may only be observed in significant amounts 
of HLC dosage, which may had been avoided after a percentage of HLC became 
unviable in the host liver. While the bright field IHC had shown evidence of 
viable HLC, the amount or spread of HLC could not be quantified. Florescent 
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microscopy, such as that of Figure 5, may had been a better method to quantify 
the amount of HLC present in the host liver.  
Nevertheless, this study’s findings do suggest the insignificant toxicity of 
transplanted HLC in a xeno-transplanted host. No statistical significant 
difference in the first few days were observed for the LFT, as the amount of 
viable HLC would had been the highest. Any cellular toxicity caused by HLC 
would also had been detected along the transplant interface due to local effects.  
Collagen Scaffold Delivery Effectiveness 
During the team’s earlier research, different cell delivery methods were 
explored. HLC were transplanted intravenously into the liver, however, due to 
the “sticky” epithelial nature of HLC, the cells were found to accumulate in the 
hepatic portal venous system. This caused portal hypertension, leading to 
overall poor outcomes. Intraperitoneal infusion was also attempted. However, 
the HLC could not be localized to the liver, creating difficulties for further 
analysis on the cells.  
This study had shown that using collagen scaffold, as a unique cell delivery 
vehicle, to be successful from the survival of HLC in xeno-transplanted host for 
3 weeks’ post-transplantation. However, the effectiveness of cell delivery was 
low. This is seen in Figure 20 where the inner layers of the collagen scaffold 
were not penetrated with HLC attaching to the collagen scaffold superficially. 
Collagen sandwich extra-cellular matrix, a system which has been well studied 
for the maintenance of mature hepatocyte function, is suggested for future 
works of HLC [64]. This too prevents the HLC from “escaping” to non-intended 
sites and mechanical injuries during surgical application.   




Enhancement on Liver Regeneration 
Despite not being able to detect any significant statistical difference in 
enhancement effects on liver regeneration for this small sample size study, a 
faster recovery trend seemed to be developing for the study arm. The study arm 
subjects may had suffered from a higher level of trauma during the hepatectomy, 
suggested by the higher DeRitis’ Ratio in the first few days after the surgery. 
The ratio for the study arm dropped faster to reach the same level as that of the 
control arm in post-operative day 4. Certain ALP isoenzyme are clinically 
observed to be elevated which indicates for favourable liver regeneration. This 
may had been the case for the study arm during its recovery phase.  
Nevertheless, several factors can be improved on to achieve the desired 
enhancement effect. Firstly, a significant amount of HLC may had “escaped” 
from the collagen scaffold during the initial period of transplantation. This is 
due to the superficial attachment of the HLC to the collagen scaffold observed. 
Furthermore, fibrous tissue was forming on the transplant interface, a part of the 
regenerative process of the host liver. This could have impeded any mitogenic 
effects HLC has on the host hepatocytes or assisting in the hepatocyte functions, 
in later periods of transplantation. This is where a multiple-layered sandwich 
collagen scaffold may be a solution to these problems. HLC will be confined in 
the scaffold and, similar to a delayed-release tablet, as the initial layers of 
collagen are being absorbed, HLC will continue to be exposed to host 
hepatocytes as the fibrous tissue degenerates during the later periods of the 
regeneration process.  
Secondly, the injury caused to the host liver may had not been severe enough. 
Discussed above, proliferation of hepatocytes is the main mechanism of liver 
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repair and regeneration. Liver stem cells only come into play when there is 
insufficient hepatocyte proliferation activity. The porcine subjects used in this 
study were healthy and the strong organic hepatocyte regeneration may had 
overpowered any regenerative effects HLC had on the host liver. 50% 
hepatectomy procedure was the most severe surgical intervention the team 
could carried out due to survival risks on the subject.  It is suggested that 
hepatotoxins, such as CCl4, be administered in future studies to create a more 
severe liver insufficient model.  
Thirdly, the HLC were not metabolically competent enough as compared to a 
mature hepatocyte. During the earlier study performed on in-vitro HLC, it was 
found that the metabolic enzyme expressions of HLC were approximately 70% 
lower compared to that of matured hepatocytes [60]. More work will have to be 
done to optimize the competency of HLC during the hepatogenesis stage. A 
benefit of using CLEC for cell therapy is the large number of viable cells 
obtained. With the insignificant toxicity levels of HLC, a large concentration of 













This study is the first step of the team’s goal to use HLC, derived from CLEC, 
as a mean to enhance liver regeneration, before the liver worsens to a stage in 
which regeneration is not possible This study has shown the safety of 
transplanting HLC into an immunologically-competent xeno-transplanted host. 
It is also successful in showing the unique cell delivery method – applying 
collagen scaffold with HLC directly on the liver parenchyma surface – with the 
survival of the transported cells 3 weeks’ post-transplantation. More 
investigations will have to be performed to show that HLC has a significant 
positive effect on liver regeneration. No doubt, this will be a long and arduous 
journey, but for patients suffering from liver diseases, this is a worthwhile effort.  
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Immunohistochemistry Protocol for Paraffin sections 
1. Deparaffinize sections: 2 changes of xylene, 10 minutes each 
 
2. Rehydrate: 2 changes of absolute alcohol, 5 minutes each, 95% alcohol for 
2 minutes and 70% alcohol for 2 minutes. 
 
3. Antigen expose epitope using citrate buffer (pH 6.1) at 121 °C for 40 
minutes. 
 
4. Block endogenous peroxides: 15 minutes at room temperature in 3% H2O2 
in PBS. 
 
5. 10% Goat serum in PBS-T, block for 30 minutes. 
 
6. 1st Antibody: Dilute 1st Ab in antibody diluents, apply 50ul/section. 
Incubate overnight at 4 °C in humid chamber. 
 
7. Wash slides in gentle running tap water for 10 minutes. 
 
8. Rinse in PBS-T for 5 minutes. 
 
9. 2nd Antibody: Dilute 2nd Ab in antibody diluents, apply 50ul/section. 
Incubate for 30 minutes at room temperature in humid chamber. 
 
10. Wash slides in gentle running tap water for 10 minutes. 
 
11. Rinse in PBS-T for 5 minutes. 
 
12. Incubate sections in DAB for 5 minutes. 
 
13. Drain and rinse under deionized water to stop DAB reaction. 
 
14. Counter stain with hematoxylin: 10 quick dips in hematoxylin, Rinse with 
dH2O, Develop in tap water for 5 minutes, Dip 5 times in acid ethanol, 
Rinse in tap water for 2 minutes, Rinse with dH2O for 2 minutes. 
 
15. Dehydrate through 95% alcohol, 2 changes of absolute alcohol, 5 minutes 
each. 
 
16. Clear in 2 changes of xylene, 5 minutes each. 
 











Table 2: Raw LFT data of subject CARE9 from control group. 
CARE9 
Result 

















PT 13.1 14.7 13.7 11.9 12.8 13.2 * 12.9 secs 
INR 1.04 1.21 1.11 0.92 1.01 1.05 * 1.02 INR 
ALB 26 29 27 30 33 38 32 30 g/L 
TBIL 2 15 6 3 2 2 2 2 umol/L 
DB 1 10 5 2 1 1 1 2 umol/L 
IB 1 5 1 1 1 1 1 0 umol/L 
AST 28 670 212 60 39 86 91 35 U/L 
ALT 51 113 95 90 73 89 79 62 U/L 
ALP 123 224 223 178 153 142 130 98 U/L 
LDH 902 2682 1757 1613 1268 1664 1824 988 U/L 
* – Lack of data due to technical difficulties (e.g. clotted blood tubes, dysfunctional portal catheter)  
 
Table 3: Raw LFT data of subject CARE12 from control group. 
CARE12 
Result 

















PT 13.6 15.2 13.3 12.8 12.4 13.3 14 * secs 
INR 1.09 1.27 1.06 1.01 0.97 1.06 1.14 * INR 
ALB 21 29 30 30 31 31 31 26 g/L 
TBIL 2 14 2 2 2 2 2 2 umol/L 
DB 1 11 2 1 2 1 1 2 umol/L 
IB 1 3 0 1 0 1 1 0 umol/L 
AST 51 747 334 113 72 46 63 68 U/L 
ALT 41 106 109 104 93 80 70 43 U/L 
ALP 94 250 210 125 100 77 90 106 U/L 
LDH 1321 2914 2321 2358 1919 1410 1368 1144 U/L 
* – Lack of data due to technical difficulties (e.g. clotted blood tubes, dysfunctional portal catheter)  
 
Table 4: Raw LFT data of subject ADD2 from control group. 
ADD2 
Result 

















PT 14.8 14.6 13.1 12.8 14.1 12.7 12.5 * secs 
INR 1.20 1.18 1.03 1.00 1.13 0.99 0.97 * INR 
ALB 15 23 24 25 28 27 25 * g/L 
TBIL 2 15 3 3 3 2 3 * umol/L 
DB 1 5 1 1 1 1 1 * umol/L 
IB 1 10 2 2 2 1 2 * umol/L 
AST 111 292 135 52 56 39 54 * U/L 
ALT 50 105 114 98 100 76 50 * U/L 
ALP 117 276 251 281 462 305 122 * U/L 
LDH 904 2217 2190 1681 1748 1533 1647 * U/L 
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Table 5: Raw LFT data of subject ADD3 from control group. 
ADD3 
Result 
















PT * 13.5 12.4 13.4 13.0 11.9 13.3 N/A secs 
INR * 1.07 0.96 1.06 1.02 0.91 1.05 N/A INR 
ALB 19 29 26 26 20 15 N/A N/A g/L 
TBIL 2 11 4 3 7 5 N/A N/A umol/L 
DB 1 3 1 1 2 1 N/A N/A umol/L 
IB 1 8 3 2 5 4 N/A N/A umol/L 
AST 227 565 200 52 172 74 N/A N/A U/L 
ALT 59 116 113 95 67 41 N/A N/A U/L 
ALP 127 301 256 177 199 89 N/A N/A U/L 
LDH 1335 4689 2503 1913 1923 1370 N/A N/A U/L 
* – Lack of data due to technical difficulties. N/A – Subject was euthanized before testing  
 
Table 6: Raw LFT data of subject CARE10 from study group. 
CARE10 
Result 

















PT 12.5 14.7 13.4 13.3 12.8 12.3 13.3 * secs 
INR 0.98 1.21 1.07 1.06 1.01 0.96 1.06 * INR 
ALB 30 32 32 29 28 33 31 * g/L 
TBIL 2 5 6 5 2 2 2 * umol/L 
DB 1 4 4 3 2 1 1 * umol/L 
IB 1 1 2 2 0 1 1 * umol/L 
AST 227 2641 1038 202 82 128 133 * U/L 
ALT 63 164 159 112 92 97 81 * U/L 
ALP 93 276 331 267 195 130 100 * U/L 
LDH 994 9057 3262 2101 1434 1650 1445 * U/L 
* – Lack of data due to technical difficulties (e.g. clotted blood tubes, dysfunctional portal catheter) 
 
Table 7: Raw LFT data of subject CARE11 from study group. 
CARE11 
Result 

















PT 12.4 14 * 11.9 12.8 13.2 * * secs 
INR 0.97 1.14 * 0.92 1.01 1.05 * * INR 
ALB 23 26 29 30 33 38 * * g/L 
TBIL 2 12 3 3 2 2 * * umol/L 
DB 1 8 2 2 1 1 * * umol/L 
IB 1 4 1 1 1 1 * * umol/L 
AST 27 811 306 60 39 86 * * U/L 
ALT 60 192 212 90 73 89 * * U/L 
ALP 102 192 187 178 153 142 * * U/L 
LDH 981 5491 3111 1613 1268 1664 * * U/L 
* – Lack of data due to technical difficulties (e.g. clotted blood tubes, dysfunctional portal catheter) 
 
Table 8: Raw LFT data of subject CARE14 from study group. 
CARE14 
Result 














PT 12.1 13.9 13.9 13 12.6 13.1 13.3 N/A secs 
INR 0.94 1.13 1.13 1.03 0.99 1.04 1.06 N/A INR 
ALB 28 31 30 24 25 28 16 N/A g/L 
TBIL 2 21 12 10 13 6 2 N/A umol/L 
DB 1 13 9 8 10 5 2 N/A umol/L 
IB 1 8 3 2 3 1 0 N/A umol/L 
AST 148 2073 864 163 85 51 138 N/A U/L 
ALT 60 170 132 78 60 68 68 N/A U/L 
ALP 89 375 312 227 207 182 86 N/A U/L 
LDH 1160 11000 3859 1885 1622 1459 1852 N/A U/L 
N/A – Subject was euthanized before testing  




Table 9: Raw LFT data of subject ADD4 from study group. 
ADD4 
Result 

















PT 13.1 13.6 12.9 12.2 11.9 12.7 13.1 11.8 secs 
INR 1.03 1.08 1.01 0.94 0.91 0.99 1.03 0.90 INR 
ALB 20 31 30 30 32 26 21 30 g/L 
TBIL 3 12 9 3 4 3 4 3 umol/L 
DB 1 4 3 1 1 1 1 1 umol/L 
IB 2 8 6 2 3 2 3 2 umol/L 
AST 137 556 178 59 46 30 27 27 U/L 
ALT 60 129 140 124 105 66 50 77 U/L 
ALP 163 395 314 269 232 153 106 123 U/L 
LDH 1553 4437 2300 1819 1884 1116 883 951 U/L 
 
Table 10: Raw LFT data of subject ADD6 from study group. 
ADD6 
Result 

















PT 17.8 14.7 12.8 13.2 12.5 13.2 13.0 13.0 secs 
INR 1.52 1.19 1.00 1.05 0.98 1.05 1.03 1.03 INR 
ALB 15 25 27 27 33 26 27 31 g/L 
TBIL 2 11 3 3 3 4 4 4 umol/L 
DB 1 4 1 1 3 1 1 1 umol/L 
IB 1 7 2 2 0 3 3 3 umol/L 
AST 139 2202 876 118 70 53 34 43 U/L 
ALT 35 181 226 173 165 103 71 80 U/L 
ALP 77 239 198 123 120 92 66 74 U/L 
LDH 863 13751 5633 3287 3247 2001 1241 1232 U/L 
 
Table 11: Raw LFT data of subject ADD7 from study group. 
ADD7 
Result 

















PT 15.4 15.0 13.4 13.4 13.4 13.3 13.2 12.7 secs 
INR 1.27 1.23 1.07 1.07 1.07 1.06 1.05 1.00 INR 
ALB 19 32 30 33 29 25 27 32 g/L 
TBIL 2 10 4 4 3 4 3 3 umol/L 
DB 1 3 1 1 1 1 1 1 umol/L 
IB 1 7 3 3 2 3 2 2 umol/L 
AST 161 1072 455 97 42 57 32 37 U/L 
ALT 51 176 181 167 106 87 79 84 U/L 
ALP 93 248 211 126 90 99 139 150 U/L 
LDH 1115 9757 3260 2386 1643 1477 1300 1408 U/L 
 
Table 12: Raw LFT data of subject ADD9 from study group. 
ADD9 
Result 

















PT 12.9 15 13.5 * * 13.5 13.8 13.1 secs 
INR 1.02 1.23 1.08 * * 1.08 1.11 1.04 INR 
ALB 18 28 29 * * 23 22 27 g/L 
TBIL 3 9 3 * * 3 3 5 umol/L 
DB 1 3 1 * * 1 1 1 umol/L 
IB 2 6 2 * * 2 2 4 umol/L 
AST 104 773 314 * * 30 41 28 U/L 
ALT 49 142 157 * * 69 52 65 U/L 
ALP 115 241 229 * * 94 99 92 U/L 
LDH 1214 4247 2258 * * 1041 936 948 U/L 
* – Lack of data due to technical difficulties (e.g. clotted blood tubes, dysfunctional portal catheter) 
 





Table 13: Raw liver volume data of porcine subjects. 
Liver Volume (ml) 
Result Pre-Op Post-Op POD8 POD15 POD21* 
CONTROL 
CARE9 1226.8 522.8 940.5 1109.3 1000 
CARE12 1044.5 498.2 876.3 904.1 1100 
ADD2 719 550 684 826 711.9 
ADD3 835 471 760 496 N/A 
STUDY 
CARE10 1223 489.8 974.2 1117 1100 
CARE11 1459.5 801.4 1166.2 1267.3 1200 
CARE14 1156.3 296.2 701 643.3 N/A 
ADD4 839 688 783 867 711.9 
ADD6 787 573 884 863 762.75 
ADD7 730 594 804 724 734.5 
ADD9 684 397 651 740 576.3 
N/A – Subject was euthanized before testing.  
* – Additional 13% volume was accounted for water displacement method.  
 
 
